Biblio

Found 7 results
Filters: Author is Gigi Hirsch  [Clear All Filters]
2021
H. - G. Eichler, Trusheim, M., Schwarser-Daum, B., Larholt, K., Zeitlinger, M., Brunninger, M., Sherman, M., Strutton, D., and Hirsch, G., “Precision reimbursement for precision medicine: using real world evidence to evolve from trial-and-project to track-and-pay to lean-and-predict”, Clinical Pharmacology & Therapeutics, 2021.
2019
G. Hirsch, “Leaping Together Toward Sustainable, Patient-Centered Innovation: The Value of a Multistakeholder Safe Haven for Accelerating System Change”, Clinical Pharmacology & Therapeutics, vol. 105, no. 4, 2019.
2016
D. Schulthess, Baird, L. G., Trusheim, M., Unger, T. F., Lumpkin, M., Hoos, A., Garner, S., Gavin, P., Goldman, M., Seigneuret, N., Chlebus, M., Van Baelen, K., Bergstrom, R., and Hirsch, G., “Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation”, Therapeutic Innovation & Regulatory Science, vol. 50, pp. 347-354, 2016.
2014
R. J Teagarden, Unger, T. F., and Hirsch, G., “Access and availability of orphan drugs in the United States: advances or cruel hoaxes?”, Expert Opinion on Orphan Drugs, vol. 2, pp. 1147-1150, 2014.
M. R. Trusheim, Baird, L. G., Garner, S., Lim, R., Patel, N., and Hirsch, G., “The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions”, Health Policy and Technology, vol. 3, pp. 241 - 247, 2014.
2013
L. Baird and Hirsch, G., “Adaptive licensing: creating a safe haven for discussions”, Scrip Regulatory Affairs, 2013.
L. G. Baird, Trusheim, M. R., Eichler, H. - G., Berndt, E. R., and Hirsch, G., “Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development”, Therapeutic Innovation & Regulatory Science, vol. 47, pp. 474-483, 2013.